Comparative Pharmacology
Head-to-head clinical analysis: OXACILLIN SODIUM versus SPECTROBID.
Peer-Reviewed Evidence
Head-to-head clinical analysis: OXACILLIN SODIUM versus SPECTROBID.
OXACILLIN SODIUM vs SPECTROBID
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Oxacillin is a penicillinase-resistant beta-lactam antibiotic that inhibits bacterial cell wall synthesis by binding to penicillin-binding proteins (PBPs), thereby blocking the transpeptidation step in peptidoglycan cross-linking. It is resistant to staphylococcal beta-lactamase.
Spectrobird (bacampicillin) is a prodrug of ampicillin, a beta-lactam antibiotic that inhibits bacterial cell wall synthesis by binding to penicillin-binding proteins (PBPs), leading to cell lysis and death.
1-2 grams IV every 4-6 hours.
400 mg orally twice daily or 200 mg orally four times daily for 10-14 days. For acute exacerbations of chronic bronchitis: 400 mg orally twice daily for 10 days.
None Documented
None Documented
0.3-0.8 hours in adults with normal renal function; prolonged to 1-2 hours in neonates and 2-5 hours in patients with severe renal impairment (CrCl <10 mL/min)
Terminal elimination half-life: 1.5-2 hours in normal renal function; prolonged to 6-10 hours in severe renal impairment (CrCl <10 mL/min).
Renal (70-80% unchanged by tubular secretion and glomerular filtration); biliary (minor, approximately 10%)
Renal: ~75-85% unchanged drug; fecal/biliary: ~15-25% as metabolites and unchanged drug.
Category A/B
Category C
Penicillin Antibiotic
Penicillin Antibiotic